GSK3B and glioma: found that AURKA competes with β-catenin for AXIN binding, disrupting the degradation complex composed of AXIN, GSK3β and β-catenin, leads to increased β-catenin protein stability and activation of the Wnt signaling pathway in glioma cells (66).